Related references
Note: Only part of the references are listed.RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer
Teodora Radonic et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Revisiting Risk and Benefit in Early Oncology Trials in the Era of Precision Medicine: A Systematic Review and Meta-Analysis of Phase I Trials of Targeted Single-Agent Anticancer Therapies
Michael P. Mackley et al.
JCO PRECISION ONCOLOGY (2021)
From Tissue-Agnostic to N-of-One Therapies:(R)Evolution of the Precision Paradigm
Jacob J. Adashek et al.
TRENDS IN CANCER (2021)
Small molecules, big impact: 20 years of targeted therapy in oncology
Philippe L Bedard et al.
LANCET (2020)
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
Shumei Kato et al.
NATURE COMMUNICATIONS (2020)
The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data
Axel Bengtsson et al.
SCIENTIFIC REPORTS (2020)
Oncologist Confidence in Genomic Testing and Implications for Using Multimarker Tumor Panel Tests in Practice
Janet S. de Moor et al.
JCO PRECISION ONCOLOGY (2020)
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
Dominic G. Rothwell et al.
NATURE MEDICINE (2019)
A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients
Michael J. Pishvaian et al.
JAMIA OPEN (2019)
Comprehensive Characterization of Cancer Driver Genes and Mutations
Matthew H. Bailey et al.
CELL (2018)
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J. Mateo et al.
ANNALS OF ONCOLOGY (2018)
An explorative phase 2 study of afatinib for advanced cancers carrying an EGFR, a HER2 or a HER3 mutation: A Precision trial of the Belgian Society of Medical Oncology.
Lore Decoster et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
Christophe Massard et al.
CANCER DISCOVERY (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
Andrew J. Aguirre et al.
CANCER CELL (2017)
Implementing Genome-Driven Oncology
David M. Hyman et al.
CELL (2017)
Mapping inhibitor response to the in-frame deletions, insertions and duplications of epidermal growth factor receptor (EGFR) in non-small cell lung cancer
Jingheng Ning et al.
JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION (2016)
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
Christian Dittrich et al.
ESMO OPEN (2016)
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
Maria Schwaederle et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Rare cancers are not so rare: The rare cancer burden in Europe
Gemma Gatta et al.
EUROPEAN JOURNAL OF CANCER (2011)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)